A securities class action lawsuit has been initiated against Inovio Pharmaceuticals, Inc. (INO) alleging that the company issued materially false statements regarding its CELLECTRA device manufacturing capabilities and the regulatory trajectory of its lead candidate, INO-3107. The allegations center on representations made to investors that preceded significant adverse developments in the company's regulatory proceedings.
On December 29, 2025, the U.S. Food and Drug Administration rejected Inovio's request for accelerated approval of INO-3107, instead designating the application for standard review. This regulatory setback triggered a substantial market reaction, with Inovio's stock price declining 24.45% following the announcement. The shift from accelerated to standard review status represents a material change in the anticipated timeline for the drug candidate's potential market entry.
Investors who purchased Inovio securities during the relevant period and believe they sustained losses as a result of the alleged misstatements have until April 7, 2026 to petition the court for lead plaintiff status in the class action. Legal representatives handling the matter are encouraging affected shareholders to review their investment positions and consider their rights under applicable securities laws.